COMPASS Pathways

COMPASS Pathways

Pharmaceuticals
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.

$1.5B

Market Cap • 10/16/2026

2020

(6 years)

Founded

2020

(6 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United Kingdom

United Kingdom

Country

Valuation

P/B

17,6

P/S

—

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

0,6

EPS

—

Market Cap

Market Cap

1,5B

EV

1,1B

EV/Revenue

0

EV/EBITDA

-6,1

EV/EBIT

-6,1

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-23,6%

Total Yield

-23,6%

Payout

0%

Retained Earnings

-985,2M

Profitability

Gross Margin

—

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

0%

Capex/Revenue

0%

Capex/D&A

0%

Capex/OCF

0%

SBC/OCF

—

% PPE

0,8%

% Goodwill

0%

ROE

—

ROIC

—

Growth

CAGR Op. Income 5Y

25,6%

CAGR Net Income 5Y

43,1%

CAGR EPS 5Y

12,1%

CAGR OCF 5Y

21%

Leverage

N.D./EBITDA

2,1

Debt/Equity

0%

Current Ratio

1,3

Quick Ratio

1,2

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium